Page 22 - 73_01

MARÍA JOSÉ GÓMEZ-LECHÓN y MARÍA TERESA DONATO AN. R. ACAD. NAC. FARM.

(35) BORT, R.; MACÉ, K.; BOOBIS, A.; GÓMEZ-LECHÓN, M. J.; PFEIFER, A. and CASTELL,
(36) J. V. (1999): Hepatic metabolism of diclofenac. Role of human CYPs in the
(37) minor oxidative pathways. Biochem. Pharmacol. 58: 787-796.
(38) EMOTO, C.; MURASE, K. and IWASAKI, K. (2006): Approach to the prediction of
the contribution of major cytochrome P450 enzymes to drug metabolism in
(39) the early drug-discovery stage. Xenobiotica. 36: 671-683.
CHANG, Y.; MOODY, D. E. and MCCAMCE-KATZ, E. F. (2006): Novel metabolites
(40) of buprenorphine detected in human liver microsomes and human urine.
(41) Drug Metab. Dispos. 34: 440-448.
(42) NARITOMI, Y.; TERASHITA, S. and KAGAYAMA, A. (2004): Identification and relative
(43) contributions of human cytochrome P450 isoforms involved in the
(44) metabolism of glibenclamide and lansoprazole: evaluation of an approach
based on the in vitro substrate disappearance rate. Xenobiotica. 34: 415-427.
(45) VENKATAKRISHNAN, K.; VON MOLTKE, L. L. and GREENBLATT, D. J. (2001):
Application of the relative activity factor approach in scaling from
(46) heterologously expressed cytochromes p450 to human liver microsomes:
studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 297:
(47) 326-37.
(48) SINGH, S. S. (2006): Preclinical pharmacokinetics: an approach towards safer
and efficacious drugs. Curr. Drug Metab. 7: 165-182.
LIN, J. H. and LU, A. Y. H. (1998): Inhibition and induction of cytochrome
P450 and the clinical implications. Clin. Pharmacokinet. 35. 361-390.
DONATO, M. T. and GÓMEZ-LECHÓN, M. J. (2006): Inhibition of P450 enzymes:
An in vitro approach. Curr. Enzyme Inhibition. 2: 281-304.
CRESPI, C. L.; MILLER, V. P. and PENMAN, B. W. (1997): Microtiter plate assays
for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem.
248: 188-190.
MOODY, G. C.; GRIFFIN, S. J.; MATHER, A. N.; MCGINNITY, D. F. and RILEY, R. J.
(1999): Fully automated analysis of activities catalysed by the major human
liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition
potential. Xenobiotica 29: 53-75.
ATKINSON, A.; KENNY, J. R. and GRIME, K. (2005): Automated assessment of
time-dependent inhibition of human cytochrome P450 enzymes using liquid
chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos.
33: 1637-1647.
NOEMIR, A. A.; RUEGG, C.; SHOEMAKER, M.; FAVREAU, L. V.; PALAMANDA, J. R.,
SILBER, P. and LIN, C. C. (2001): Inhibition of CYP3A4 in a rapid microtiter
plate assay using recombinant enzyme and in human liver microsomes using
conventional substrates. Drug Metab. Dispos. 29: 748-753.
ITO, K.; IWATSUBO, T.; KANAMITSU, S.; UEDA, K.; SUZUKI, H. and SUGIYAMA, H.
(1998): Prediction of pharmacokinetic alterations caused by drug-drug
interactions: metabolic interaction in the liver. Pharmacol. Rev. 50: 387-412.
PELKONEN, O.; TURPEINEN, M.; UUSITALO, J.; RAUTIO, A. and RAUNIO, H. (2005):
Prediction of drug metabolism and interactions on the basis of in vitro
investigations. Basic Clin. Pharmacol. Toxicol. 96: 167-175.

24